An integrated early formulation strategy - From hit evaluation to preclinical candidate profiling

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 66, Issue 1, 2007, Pages 1-10

  Maas, Jochen ^a   Kamm, Walter ^a   Hauck, Gerrit ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Customized vehicles; Early formulation strategy; Enabling formulations; Harmonization; Physical chemical properties; Poor solubility compounds; Standard formulations

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALCOHOL; CHLORTETRACYCLINE; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; DRUG VEHICLE; GELUCIRE; GLYCEROL; HYDROXYETHYLCELLULOSE; LABRASOL; LIPOFUNDIN; MACROGOL; MACROGOL 400; METHYLCELLULOSE; MIGLYOL; NANOCRYSTAL; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; PROPYLENE GLYCOL; SOYBEAN OIL; SURFACTANT;

ACIDITY; ALKALINITY; AQUEOUS SOLUTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG QUALITY; DRUG SOLUBILITY; EMULSION; EVALUATION; MICELLE; NONHUMAN; PHYSICAL CHEMISTRY; PKA; REVIEW; SOLID STATE; TEAMWORK; TOXICITY TESTING;

ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 33947174194     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.09.011     Document Type: Review

References (30)

1. Gaviraghi G., Burnaby R.T., and Pellegatti M. Pharmacokinetic Challenges in Lead Optimization. In: Testa B., van de Waterbeemd H., Folkers G., and Guy R. (Eds). Pharmacokinetic Optimization in Drug Research (2001), Verlag Helvetica Chimica Acta, Zürich pp. 3-14
2. Peck C.C., Barr W.H., Benet L.Z., Collins J., Desjardins R.E., Furst D.E., Harter J.G., Levy G., Ludden T., and Rodman J.H. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51 (1992) 465-473
3. Pritchard J.F., Jurima-Romet M., Reimer M.L.J., Mortimer E., Rolfe B., and Cayen M.N. Making better drugs: decision gates in non-clinical drug development. Nat. Rev. Drug Discov. 2 (2003) 542-553
4. Balbach S., and Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int. J. Pharm. 275 (2004) 1-12
5. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44 (2000) 235-249
6. Sakaeda T., Okamura N., Nagata S., Yagami T., Horinouchi M., Okumura K., Yamashita F., and Hashida M. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. Biol. Pharm. Bull. 24 (2001) 935-940
7. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
8. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
9. Kerns E.H., and Di L. Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. 2 (2002) 87-98
10. van de Waterbeemd H. High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Dev. 5 (2002) 33-43
11. Lee Y.- C., Zocharski P.D., and Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253 (2003) 111-119
12. Chaubal M.V. Application of formulation technologies in lead candidate selection and optimization. Drug Discov. Today 9 (2004) 603-609
13. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. 1 (2001) 277-351
14. Kamm W., Hauptmann J., Behrens I., Stürzebecher J., Dullweber F., Gohlke H., Stubbs M., Klebe G., and Kissel T. Transport of peptidomimetic thrombin inhibitors with a 3-amino-phenylalanine structure: permeability and efflux mechanism in monolayers of a human intestinal cell line (Caco-2). Pharm. Res. 18 (2001) 1110-1118
15. Burton P.S., Conradi R.A., Hilgers A.R., Ho N.F.H., and Maggiora L.L. The relationship between peptide structure and transport across epithelial cell monolayers. J. Contr. Rel. 19 (1992) 87-98
16. Palm K., Luthman K., Ungell A.L., Strandlund G., and Artursson P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 85 (1996) 32-39
17. Conradi R.A., Burton P.S., and Borchardt R.T. Physico-chemical and biological factors that influence a drug's cellular permeability by passive diffusion. Methods Princ. Med. Chem. (1996) 233-252
18. van-de-Waterbeemd H., and Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat. Rev. Drug Discov. 2 (2003) 192-204
19. J. Cunningham, E. Merisko-Liversidge, E.R. Cooper, G.G. Liversidge, Milling microgram quantities of nanoparticulate candidate compounds, PCT/US2003/039941.
20. Rabinow B.E. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3 (2004) 785-796
21. Miyazaki S., Arita T., Hori R., and Ito K. Effect of polymorphism on the dissolution behavior and gastrointestinal absorption of chlortetracycline hydrochloride. Chem. Pharm. Bull. 22 (1974) 638-642
22. Johnson K.C., and Swindell A.C. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm. Res. 13 (1996) 1795-1798
23. Lee V.H.L., Yamamoto A., and Kompella U.B. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit. Rev. Ther. Drug Carrier Syst. 8 (1991) 91-192
24. Aungst B.J., Saitoh H., Burcham D.L., Huang S.-M., Mousa S.A., and Hussain M.A. Enhancement of the intestinal absorption of peptides and nonpeptides. J. Contr. Rel. 41 (1996) 19-31
25. Leone-Bay A., Paton D.R., and Weidner J.J. The development of delivery agents that facilitate the oral absorption of macromolecular drugs. Med. Res. Rev. 20 (2000) 169-186
26. Derendorf H., Lesko L.J., Chaikin P., Colburn W.A., Lee P., Miller R., Powell R., Rhodes G., Stanski D., and Venitz J. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J. Clin. Pharmacol. 40 (2000) 1399-1418
27. Yu H., and Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug-Discov. Today 8 (2003) 852-861
28. Galia E., Nicolaides E., Hoerter D., Lobenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
29. W.Kamm, R. Roessler, Formulation Toolbox for animal studies- an overview about formulation strategies at early development stages, Aventis Pharma Deutschland GmbH, Pharmaceutical Sciences Frankfurt (2002, unpublished document).
30. Kipp E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 284 (2004) 109-122